Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.43 |
| ▸ | PDE4A | P27815 | 11/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253992 | 0.92 | PDE4B (0.39) | PDE4BPDE4DPDE4APDE4CNAMPT | |
| SCHEMBL3205302 | 0.89 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL3216063 | 0.88 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL1157639 | 0.85 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CEPHX2 | |
| SCHEMBL3214801 | 0.85 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3121031 | 0.85 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL3215150 | 0.84 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL3216268 | 0.83 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3205698 | 0.82 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3132055 | 0.80 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4CEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.